Brief: Amarin Partner Eddingpharm Receives Regulatory Approval For Vascepa In Mainland China
01/06/2023 11:08
June 1 (Reuters) - Amarin Corporation PLC AMRN.O :
* AMARIN PARTNER EDDINGPHARM RECEIVES REGULATORY APPROVAL
FOR
VASCEPA® (ICOSAPENT ETHYL) IN MAINLAND CHINA
* AMARIN CORPORATION PLC - VASCEPA APPROVED BY NMPA AS
ADJUNCT TO
DIET TO REDUCE TRIGLYCERIDE LEVELS IN ADULT PATIENTS WITH SEVERE
HYPERTRIGLYCERIDEMIA
* AMARIN CORP: COMMERCIAL PARTNER EDDINGPHARM WORKING
TOWARDS
PREPARING FOR COMMERCIAL LAUNCH OF VASCEPA ACROSS MAINLAND CHINA
EXPECTED BY YEAR-END
Source text for Eikon: ID:nGNXxvSyV
Further company coverage: AMRN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Amarin
See all newsAmarin Corporation PLC reports results for the quarter ended June 30 - Earnings Summary
Ireland's Amarin Q2 revenue falls on lower licensing payments
Amarin Corporation PLC expected to post a loss of 1 cent a share - Earnings Preview
US Supreme Court backs generic drugmaker in 'skinny label' patent case (updated)
US Supreme Court backs generic drugmaker in 'skinny label' patent case